Haematologica (Nov 2016)

Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura

  • Wenjing Cao,
  • Huy P. Pham,
  • Lance A. Williams,
  • Jenny McDaniel,
  • Rance C. Siniard,
  • Robin G. Lorenz,
  • Marisa B. Marques,
  • X. Long Zheng

DOI
https://doi.org/10.3324/haematol.2016.149021
Journal volume & issue
Vol. 101, no. 11

Abstract

Read online

Acquired thrombotic thrombocytopenic purpura is primarily caused by the deficiency of plasma ADAMTS13 activity resulting from autoantibodies against ADAMTS13. However, ADAMTS13 deficiency alone is often not sufficient to cause acute thrombotic thrombocytopenic purpura. Infections or systemic inflammation may precede acute bursts of the disease, but the underlying mechanisms are not fully understood. Herein, 52 patients with acquired autoimmune thrombotic thrombocytopenic purpura and 30 blood donor controls were recruited for the study. The plasma levels of human neutrophil peptides 1–3 and complement activation fragments (i.e. Bb, iC3b, C4d, and sC5b-9) were determined by enzyme-linked immunosorbent assays. Univariate analyses were performed to determine the correlation between each biomarker and clinical outcomes. We found that the plasma levels of human neutrophil peptides 1–3 and Bb in patients with acute thrombotic thrombocytopenic purpura were significantly higher than those in the control (P